[Featured Stock] Nexten Bio Joins Global No.1 miRNA Diabetes Treatment Developer...Expectations for Complete Cure

[Asia Economy Reporter Hyungsoo Park] Nexten Bio is showing strong performance. The news that RosVivo Therapeutics, in which it has invested, signed a Confidential Disclosure Agreement (CDA) with global diabetes treatment company Novo Nordisk for the joint development and technology export of diabetes treatments appears to have influenced the stock price.

As of 1:45 PM on the 7th, Nexten Bio is trading at 8,110 KRW, up 19.44% from the previous day.

Through the CDA, Nexten Bio plans to promote the technology export and joint development of the miRNA-based 'RSVI-301/302' diabetes treatment drug pipeline with Novo Nordisk, headquartered in Denmark, as well as U.S. pharmaceutical company Eli Lilly and Chinese diabetes specialist Tonghua Dongbao Pharmaceutical.

The company has signed a CDA with Eli Lilly in the U.S. and an MOU with Tonghua Dongbao Pharmaceutical in China to accelerate the development of diabetes treatments.

A Nexten Bio representative explained, “Preclinical results have confirmed the possibility of a complete cure for diabetes, and the new drug’s value is recognized by leading pharmaceutical companies for improving complications and side effects occurring during the treatment of type 2 diabetes.”

He added, “We will do our best to cooperate so that RosVivo’s new drug candidate, recognized by pharmaceutical companies, can be used as a new treatment option for patients suffering from diabetes.”

This content was produced with the assistance of AI translation services.